A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1995-03

AUTHORS

Gordon L. Amidon, Hans Lennernäs, Vinod P. Shah, John R. Crison

ABSTRACT

A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption. This analysis uses a transport model and human permeability results for estimating invivo drug absorption to illustrate the primary importance of solubility and permeability on drug absorption. The fundamental parameters which define oral drug absorption in humans resulting from this analysis are discussed and used as a basis for this classification scheme. These Biopharmaceutic Drug Classes are defined as: Case 1. High solubility-high permeability drugs, Case 2. Low solubility-high permeability drugs, Case 3. High solubility-low permeability drugs, and Case 4. Low solubility-low permeability drugs. Based on this classification scheme, suggestions are made for setting standards for in vitro drug dissolution testing methodology which will correlate with the in vivo process. This methodology must be based on the physiological and physical chemical properties controlling drug absorption. This analysis points out conditions under which noin vitro-in vivo correlation may be expected e.g. rapidly dissolving low permeability drugs. Furthermore, it is suggested for example that for very rapidly dissolving high solubility drugs, e.g. 85% dissolution in less than 15 minutes, a simple one point dissolution test, is all that may be needed to insure bioavailability. For slowly dissolving drugs a dissolution profile is required with multiple time points in systems which would include low pH, physiological pH, and surfactants and the in vitro conditions should mimic the in vivo processes. This classification scheme provides a basis for establishing in vitro-in vivo correlations and for estimating the absorption of drugs based on the fundamental dissolution and permeability properties of physiologic importance. More... »

PAGES

413-420

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/a:1016212804288

DOI

http://dx.doi.org/10.1023/a:1016212804288

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1037126380

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/7617530


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biological Availability", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cimetidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gastric Emptying", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "In Vitro Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Jejunum", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mathematics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Theoretical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Permeability", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pharmaceutical Preparations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piroxicam", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Solubility", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "College of Pharmacy, The University of Michigan, 48109-1065, Ann Arbor, Michigan", 
          "id": "http://www.grid.ac/institutes/grid.214458.e", 
          "name": [
            "College of Pharmacy, The University of Michigan, 48109-1065, Ann Arbor, Michigan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Amidon", 
        "givenName": "Gordon L.", 
        "id": "sg:person.014127067437.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014127067437.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "School of Pharmacy, Uppsala University, Box 580, S-751 23, Uppsala, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.8993.b", 
          "name": [
            "School of Pharmacy, Uppsala University, Box 580, S-751 23, Uppsala, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lennern\u00e4s", 
        "givenName": "Hans", 
        "id": "sg:person.01372131203.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372131203.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PDA, HFD-602, 20857, Rockville, Maryland", 
          "id": "http://www.grid.ac/institutes/grid.479064.8", 
          "name": [
            "PDA, HFD-602, 20857, Rockville, Maryland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shah", 
        "givenName": "Vinod P.", 
        "id": "sg:person.01223074603.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223074603.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "TSRL, Inc., 540 Avis Drive, Suite A, 48108, Ann Arbor, Michigan", 
          "id": "http://www.grid.ac/institutes/grid.281449.2", 
          "name": [
            "TSRL, Inc., 540 Avis Drive, Suite A, 48108, Ann Arbor, Michigan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Crison", 
        "givenName": "John R.", 
        "id": "sg:person.015752121734.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015752121734.07"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00562664", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044388678", 
          "https://doi.org/10.1007/bf00562664"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1015909716312", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038769588", 
          "https://doi.org/10.1023/a:1015909716312"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1015829128646", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047482208", 
          "https://doi.org/10.1023/a:1015829128646"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1015888813741", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040826363", 
          "https://doi.org/10.1023/a:1015888813741"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1015927004752", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042556047", 
          "https://doi.org/10.1023/a:1015927004752"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1018947113238", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051994422", 
          "https://doi.org/10.1023/a:1018947113238"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01061761", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036555799", 
          "https://doi.org/10.1007/bf01061761"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1015892621261", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035241234", 
          "https://doi.org/10.1023/a:1015892621261"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1018999130076", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002102293", 
          "https://doi.org/10.1023/a:1018999130076"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1995-03", 
    "datePublishedReg": "1995-03-01", 
    "description": "A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption. This analysis uses a transport model and human permeability results for estimating invivo drug absorption to illustrate the primary importance of solubility and permeability on drug absorption. The fundamental parameters which define oral drug absorption in humans resulting from this analysis are discussed and used as a basis for this classification scheme. These Biopharmaceutic Drug Classes are defined as: Case 1. High solubility-high permeability drugs, Case 2. Low solubility-high permeability drugs, Case 3. High solubility-low permeability drugs, and Case 4. Low solubility-low permeability drugs. Based on this classification scheme, suggestions are made for setting standards for in vitro drug dissolution testing methodology which will correlate with the in vivo process. This methodology must be based on the physiological and physical chemical properties controlling drug absorption. This analysis points out conditions under which noin vitro-in vivo correlation may be expected e.g. rapidly dissolving low permeability drugs. Furthermore, it is suggested for example that for very rapidly dissolving high solubility drugs, e.g. 85% dissolution in less than 15 minutes, a simple one point dissolution test, is all that may be needed to insure bioavailability. For slowly dissolving drugs a dissolution profile is required with multiple time points in systems which would include low pH, physiological pH, and surfactants and the in vitro conditions should mimic the in vivo processes. This classification scheme provides a basis for establishing in vitro-in vivo correlations and for estimating the absorption of drugs based on the fundamental dissolution and permeability properties of physiologic importance.", 
    "genre": "article", 
    "id": "sg:pub.10.1023/a:1016212804288", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2508276", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2511825", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1094644", 
        "issn": [
          "0724-8741", 
          "1573-904X"
        ], 
        "name": "Pharmaceutical Research", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "drug product dissolution", 
      "vivo bioavailability", 
      "drug absorption", 
      "product dissolution", 
      "high-solubility drugs", 
      "physical-chemical properties", 
      "vivo correlation", 
      "Biopharmaceutic Drug Classification", 
      "drug dissolution", 
      "dissolution profiles", 
      "oral drug absorption", 
      "low-permeability drugs", 
      "dissolution test", 
      "physiological pH", 
      "chemical properties", 
      "absorption of drugs", 
      "drug classification scheme", 
      "dissolution", 
      "vivo processes", 
      "low pH", 
      "bioavailability", 
      "absorption", 
      "pH", 
      "permeability properties", 
      "surfactants", 
      "properties", 
      "solubility", 
      "permeability results", 
      "fundamental dissolution", 
      "fundamental parameters", 
      "drugs", 
      "transport model", 
      "permeability", 
      "Noin", 
      "gastrointestinal permeability", 
      "process", 
      "primary importance", 
      "conditions", 
      "basis", 
      "analysis", 
      "parameters", 
      "drug classification", 
      "methodology", 
      "class", 
      "drug classes", 
      "correlation", 
      "importance", 
      "theoretical basis", 
      "profile", 
      "system", 
      "example", 
      "rate", 
      "results", 
      "extent", 
      "standards", 
      "point", 
      "physiologic importance", 
      "minutes", 
      "test", 
      "scheme", 
      "testing methodology", 
      "model", 
      "classification scheme", 
      "humans", 
      "suggestions", 
      "multiple time points", 
      "Case 2", 
      "Case 1", 
      "time points", 
      "Case 3", 
      "Case 4", 
      "classification"
    ], 
    "name": "A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability", 
    "pagination": "413-420", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1037126380"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/a:1016212804288"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "7617530"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/a:1016212804288", 
      "https://app.dimensions.ai/details/publication/pub.1037126380"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_306.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1023/a:1016212804288"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1016212804288'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1016212804288'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1016212804288'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1016212804288'


 

This table displays all metadata directly associated to this object as RDF triples.

247 TRIPLES      21 PREDICATES      118 URIs      101 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/a:1016212804288 schema:about N0310d05d606b4712a4ba184751822304
2 N0f2a26e0afe041d7b571157bc5fdda9b
3 N1ce5214bbffc490f92f5d2f51b850afe
4 N244f907a7ca143a08346ce9438e4d4df
5 N5bc87505b7f24074b9d7f3aa7a15e86e
6 N5ddea161b6ac4ffdb7bf154ad8b8ac52
7 N6d9651f4a9d54ca6999473e6dbf37eee
8 N9fa04391e35e44f985d44f0ebb2331c1
9 Nad9110ee0a954494892a6bfa5c50eb1b
10 Nd868e83459a440f28a30f87077808c23
11 Nfbed8ef0c4a245fa8bd1b393587079f9
12 anzsrc-for:11
13 anzsrc-for:1115
14 schema:author Neb867e05d389446e8d35137ea44d4ef8
15 schema:citation sg:pub.10.1007/bf00562664
16 sg:pub.10.1007/bf01061761
17 sg:pub.10.1023/a:1015829128646
18 sg:pub.10.1023/a:1015888813741
19 sg:pub.10.1023/a:1015892621261
20 sg:pub.10.1023/a:1015909716312
21 sg:pub.10.1023/a:1015927004752
22 sg:pub.10.1023/a:1018947113238
23 sg:pub.10.1023/a:1018999130076
24 schema:datePublished 1995-03
25 schema:datePublishedReg 1995-03-01
26 schema:description A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption. This analysis uses a transport model and human permeability results for estimating invivo drug absorption to illustrate the primary importance of solubility and permeability on drug absorption. The fundamental parameters which define oral drug absorption in humans resulting from this analysis are discussed and used as a basis for this classification scheme. These Biopharmaceutic Drug Classes are defined as: Case 1. High solubility-high permeability drugs, Case 2. Low solubility-high permeability drugs, Case 3. High solubility-low permeability drugs, and Case 4. Low solubility-low permeability drugs. Based on this classification scheme, suggestions are made for setting standards for in vitro drug dissolution testing methodology which will correlate with the in vivo process. This methodology must be based on the physiological and physical chemical properties controlling drug absorption. This analysis points out conditions under which noin vitro-in vivo correlation may be expected e.g. rapidly dissolving low permeability drugs. Furthermore, it is suggested for example that for very rapidly dissolving high solubility drugs, e.g. 85% dissolution in less than 15 minutes, a simple one point dissolution test, is all that may be needed to insure bioavailability. For slowly dissolving drugs a dissolution profile is required with multiple time points in systems which would include low pH, physiological pH, and surfactants and the in vitro conditions should mimic the in vivo processes. This classification scheme provides a basis for establishing in vitro-in vivo correlations and for estimating the absorption of drugs based on the fundamental dissolution and permeability properties of physiologic importance.
27 schema:genre article
28 schema:isAccessibleForFree true
29 schema:isPartOf N68cae8dea23e4d5faf5e068b02af4755
30 Nfba6d8f3e13741549c7ae9e74746980b
31 sg:journal.1094644
32 schema:keywords Biopharmaceutic Drug Classification
33 Case 1
34 Case 2
35 Case 3
36 Case 4
37 Noin
38 absorption
39 absorption of drugs
40 analysis
41 basis
42 bioavailability
43 chemical properties
44 class
45 classification
46 classification scheme
47 conditions
48 correlation
49 dissolution
50 dissolution profiles
51 dissolution test
52 drug absorption
53 drug classes
54 drug classification
55 drug classification scheme
56 drug dissolution
57 drug product dissolution
58 drugs
59 example
60 extent
61 fundamental dissolution
62 fundamental parameters
63 gastrointestinal permeability
64 high-solubility drugs
65 humans
66 importance
67 low pH
68 low-permeability drugs
69 methodology
70 minutes
71 model
72 multiple time points
73 oral drug absorption
74 pH
75 parameters
76 permeability
77 permeability properties
78 permeability results
79 physical-chemical properties
80 physiologic importance
81 physiological pH
82 point
83 primary importance
84 process
85 product dissolution
86 profile
87 properties
88 rate
89 results
90 scheme
91 solubility
92 standards
93 suggestions
94 surfactants
95 system
96 test
97 testing methodology
98 theoretical basis
99 time points
100 transport model
101 vivo bioavailability
102 vivo correlation
103 vivo processes
104 schema:name A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
105 schema:pagination 413-420
106 schema:productId N3b7b1534b7a4414089ec096a75177362
107 N781fc813496c42119c48e992083c3a28
108 Nf077d38eff9746a0ab705f5922d45144
109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037126380
110 https://doi.org/10.1023/a:1016212804288
111 schema:sdDatePublished 2022-08-04T16:52
112 schema:sdLicense https://scigraph.springernature.com/explorer/license/
113 schema:sdPublisher N257b137575ef47e39975f3a413c9b983
114 schema:url https://doi.org/10.1023/a:1016212804288
115 sgo:license sg:explorer/license/
116 sgo:sdDataset articles
117 rdf:type schema:ScholarlyArticle
118 N0310d05d606b4712a4ba184751822304 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Pharmaceutical Preparations
120 rdf:type schema:DefinedTerm
121 N0f2a26e0afe041d7b571157bc5fdda9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Permeability
123 rdf:type schema:DefinedTerm
124 N1ce5214bbffc490f92f5d2f51b850afe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Piroxicam
126 rdf:type schema:DefinedTerm
127 N244f907a7ca143a08346ce9438e4d4df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Cimetidine
129 rdf:type schema:DefinedTerm
130 N257b137575ef47e39975f3a413c9b983 schema:name Springer Nature - SN SciGraph project
131 rdf:type schema:Organization
132 N3b7b1534b7a4414089ec096a75177362 schema:name doi
133 schema:value 10.1023/a:1016212804288
134 rdf:type schema:PropertyValue
135 N5bc87505b7f24074b9d7f3aa7a15e86e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Solubility
137 rdf:type schema:DefinedTerm
138 N5ddea161b6ac4ffdb7bf154ad8b8ac52 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name In Vitro Techniques
140 rdf:type schema:DefinedTerm
141 N65ed29db79734cf9875be1b004697d1b rdf:first sg:person.01372131203.73
142 rdf:rest N6659d86a39904f3ba6ad93b686e88fce
143 N6659d86a39904f3ba6ad93b686e88fce rdf:first sg:person.01223074603.31
144 rdf:rest N8cc4d95e94d043c5b6fe6427ee2c1c32
145 N68cae8dea23e4d5faf5e068b02af4755 schema:issueNumber 3
146 rdf:type schema:PublicationIssue
147 N6d9651f4a9d54ca6999473e6dbf37eee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Jejunum
149 rdf:type schema:DefinedTerm
150 N781fc813496c42119c48e992083c3a28 schema:name pubmed_id
151 schema:value 7617530
152 rdf:type schema:PropertyValue
153 N8cc4d95e94d043c5b6fe6427ee2c1c32 rdf:first sg:person.015752121734.07
154 rdf:rest rdf:nil
155 N9fa04391e35e44f985d44f0ebb2331c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Gastric Emptying
157 rdf:type schema:DefinedTerm
158 Nad9110ee0a954494892a6bfa5c50eb1b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Models, Theoretical
160 rdf:type schema:DefinedTerm
161 Nd868e83459a440f28a30f87077808c23 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Mathematics
163 rdf:type schema:DefinedTerm
164 Neb867e05d389446e8d35137ea44d4ef8 rdf:first sg:person.014127067437.90
165 rdf:rest N65ed29db79734cf9875be1b004697d1b
166 Nf077d38eff9746a0ab705f5922d45144 schema:name dimensions_id
167 schema:value pub.1037126380
168 rdf:type schema:PropertyValue
169 Nfba6d8f3e13741549c7ae9e74746980b schema:volumeNumber 12
170 rdf:type schema:PublicationVolume
171 Nfbed8ef0c4a245fa8bd1b393587079f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Biological Availability
173 rdf:type schema:DefinedTerm
174 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
175 schema:name Medical and Health Sciences
176 rdf:type schema:DefinedTerm
177 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
178 schema:name Pharmacology and Pharmaceutical Sciences
179 rdf:type schema:DefinedTerm
180 sg:grant.2508276 http://pending.schema.org/fundedItem sg:pub.10.1023/a:1016212804288
181 rdf:type schema:MonetaryGrant
182 sg:grant.2511825 http://pending.schema.org/fundedItem sg:pub.10.1023/a:1016212804288
183 rdf:type schema:MonetaryGrant
184 sg:journal.1094644 schema:issn 0724-8741
185 1573-904X
186 schema:name Pharmaceutical Research
187 schema:publisher Springer Nature
188 rdf:type schema:Periodical
189 sg:person.01223074603.31 schema:affiliation grid-institutes:grid.479064.8
190 schema:familyName Shah
191 schema:givenName Vinod P.
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223074603.31
193 rdf:type schema:Person
194 sg:person.01372131203.73 schema:affiliation grid-institutes:grid.8993.b
195 schema:familyName Lennernäs
196 schema:givenName Hans
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372131203.73
198 rdf:type schema:Person
199 sg:person.014127067437.90 schema:affiliation grid-institutes:grid.214458.e
200 schema:familyName Amidon
201 schema:givenName Gordon L.
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014127067437.90
203 rdf:type schema:Person
204 sg:person.015752121734.07 schema:affiliation grid-institutes:grid.281449.2
205 schema:familyName Crison
206 schema:givenName John R.
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015752121734.07
208 rdf:type schema:Person
209 sg:pub.10.1007/bf00562664 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044388678
210 https://doi.org/10.1007/bf00562664
211 rdf:type schema:CreativeWork
212 sg:pub.10.1007/bf01061761 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036555799
213 https://doi.org/10.1007/bf01061761
214 rdf:type schema:CreativeWork
215 sg:pub.10.1023/a:1015829128646 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047482208
216 https://doi.org/10.1023/a:1015829128646
217 rdf:type schema:CreativeWork
218 sg:pub.10.1023/a:1015888813741 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040826363
219 https://doi.org/10.1023/a:1015888813741
220 rdf:type schema:CreativeWork
221 sg:pub.10.1023/a:1015892621261 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035241234
222 https://doi.org/10.1023/a:1015892621261
223 rdf:type schema:CreativeWork
224 sg:pub.10.1023/a:1015909716312 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038769588
225 https://doi.org/10.1023/a:1015909716312
226 rdf:type schema:CreativeWork
227 sg:pub.10.1023/a:1015927004752 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042556047
228 https://doi.org/10.1023/a:1015927004752
229 rdf:type schema:CreativeWork
230 sg:pub.10.1023/a:1018947113238 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051994422
231 https://doi.org/10.1023/a:1018947113238
232 rdf:type schema:CreativeWork
233 sg:pub.10.1023/a:1018999130076 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002102293
234 https://doi.org/10.1023/a:1018999130076
235 rdf:type schema:CreativeWork
236 grid-institutes:grid.214458.e schema:alternateName College of Pharmacy, The University of Michigan, 48109-1065, Ann Arbor, Michigan
237 schema:name College of Pharmacy, The University of Michigan, 48109-1065, Ann Arbor, Michigan
238 rdf:type schema:Organization
239 grid-institutes:grid.281449.2 schema:alternateName TSRL, Inc., 540 Avis Drive, Suite A, 48108, Ann Arbor, Michigan
240 schema:name TSRL, Inc., 540 Avis Drive, Suite A, 48108, Ann Arbor, Michigan
241 rdf:type schema:Organization
242 grid-institutes:grid.479064.8 schema:alternateName PDA, HFD-602, 20857, Rockville, Maryland
243 schema:name PDA, HFD-602, 20857, Rockville, Maryland
244 rdf:type schema:Organization
245 grid-institutes:grid.8993.b schema:alternateName School of Pharmacy, Uppsala University, Box 580, S-751 23, Uppsala, Sweden
246 schema:name School of Pharmacy, Uppsala University, Box 580, S-751 23, Uppsala, Sweden
247 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...